GenAI radiology workflow company Rad AI and Bayer announced a collaboration to bring Rad AI’s technology to the multinational pharmaceutical and biotechnology company’s Calantic Digital Solution customers.
Calantic is a vendor-neutral cloud-based marketplace of AI-enabled radiology apps aimed at automating routine radiology tasks.
California-based Rad AI offers radiologists generative AI tools to help streamline workflows, such as physician dictation and follow-up care management offerings.
One of its offerings is its Rad AI Omni Impressions platform, which generates AI-enabled report impressions after a radiologist dictates the raw findings. The platform continuously learns the stylistic tone and voice of each individual radiologist and generates reports with individualized, specific impression language.
Rad AI’s AI-enabled follow-up management, radiology speech recognition reporting and radiology impression generation technologies will be available to Calantic’s customers.
“Our customers consistently convey to us that a clear ROI from the use of AI will help to increase confidence and adoption. Demonstrating ROI via operational applications like those on Bayer’s Calantic Digital Solutions platform is often an easier path, which is why Bayer is excited to enter into this agreement with Rad AI,” Rich Dewit, senior vice president of digital solutions at Bayer Radiology, said in a statement.
“This technology has the ability to help physicians optimize and streamline their radiology reporting and deliver benefits for the patient and the health system.”
THE LARGER TREND
Last month, Rad AI announced a partnership with LucidHealth, a national network of radiology practices, which will utilize its Omni Impressions dictation tool throughout its community-based practices.
In January, Rad AI announced a partnership with Google Cloud, which allowed the genAI company to scale its technology using Google’s MedLM foundation models and cloud services.
In May, Rad AI secured $50 million in Series B funding, bringing its total raise to more than $80 million. In 2021, the company secured $25 million in Series A funding.
